The Ductus Arteriosus Rarely Requires Treatment in Infants > 1000 Grams

ABSTRACT

We sought to determine the rate of spontaneous closure of the ductus arteriosus (DA) in very-low-birth-weight infants. This prospective observational study included 65 infants whose birth weight (BW) < 1500 g. Echocardiograms were done on day of life (DOL) 3 and 7, weekly for the first month, and bimonthly until ligation, discharge, or death. Treatment was reserved for infants with heart failure, acute renal impairment, or those with significant persistent or escalating respiratory support. Chi-square tests, Student t tests, and logistic regression models were used to identify possible associations between spontaneous ductal closure by DOL 7 and predictor variables. Patterns of spontaneous DA closure over time were examined using Kaplan-Meier survival analysis. The DA closed spontaneously in 49% infants by DOL 7. Rates of spontaneous closure by DOL 7 differed significantly by BW strata: 67% for BW > 1000 g, 31% for BW ≤ 1000 g (p < 0.01). Ninety-seven percent of infants > 1000 g did not require intervention, and the DA closed spontaneously prior to discharge in 94%. In a logistic regression model, only BW > 1000 g and male gender were significantly associated with spontaneous closure by 1 week of life. The median time to spontaneous closure differed significantly between infants in the two BW strata: 7 days for > 1000 g versus 56 days for ≤ 1000 g (p < 0.001). Intervention for the patent DA in infants > 1000 g BW is rarely indicated. In infants ≤ 1000 g BW, deferring treatment decisions until at least 1 week of life may avoid unnecessary treatment exposure.

Ductus arteriosus - indomethacin - prematurity - ligation

REFERENCES

• 1 Clyman R I, Narayanan M. Patent ductus arteriosus: a physiologic basis for current treatment practices. In: Hansen TN, McIntosh N Current Topics in Neonatology Number 4. London, England; WB Saunders, Harcourt Publishers Limited 2000: 72-91
• 2 Ryder R W, Shelton J D, Guinan M E. The committee on necrotizing enterocolitis.  Am J Epidemiol. 1980;  112 113-123
• 3 Jones R WA, Pickering D. Persistent ductus arteriosus complicating the respiratory distress syndrome.  Arch Dis Child. 1977;  52 274-281
• 4 Neal W A, Bessinger F B, Hunt C E et al.. Patent ductus arteriosus complicating respiratory distress syndrome.  J Pediatr. 1975;  86 127-131
• 5 Hermes-DeSantis E R, Clyman R I. Patent ductus arteriosus: pathophysiology and management.  J Perinatol. 2006;  26 S14-S18
• 6 Thibeault D W, Emmanouilides G C, Nelson R J et al.. Patent ductus arteriosus complicating the respiratory distress syndrome in preterm infants.  J Pediatr. 1975;  86 120-126
• 7 Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage.  J Pediatr. 2000;  137 68-72
• 8 Chorne N, Leonard C, Piecuch R et al.. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity.  Pediatrics. 2007;  119 1165-1174
• 9 Schmidt B, Roberts R S, Fanaroff A et al.. Indomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: further analyses from the trial of indomethacin prophylaxis in preterms (TIPP).  J Pediatr. 2006;  148 730-734
• 10 Brooks J M, Travadi J N, Patole S K et al.. Is surgical ligation of patent ductus arteriosus necessary? The Western Australian experience of conservative management.  Arch Dis Child Fetal Neonatal Ed. 2005;  90 F235-F239
• 11 Laughon M M, Simmons M A, Bose C L. Patency of the ductus arteriosus in the premature infant: is it pathologic? Should it be treated?.  Curr Opin Pediatr. 2004;  16 146-151
• 12 Dudell G G, Gersony W M. Patent ductus arteriosus in neonates with severe respiratory disease.  J Pediatr. 1984;  104 915-920
• 13 Reller M D, Laird M R, Rice M J et al.. Timing of ductal closure in very low birth weight premature infants without respiratory distress.  J Pediatr. 1991;  119 976-977
• 14 Koch J, Hensley G, Roy L et al.. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 g or less.  Pediatrics. 2006;  117 1113-1121
• 15 Fenton T R. A new growth chart for preterm babies: Babson and Benda's chart updated with recent data and a new format.  BMC Pediatr. 2003;  3 13
• 16 Su Bai-Horng, Watanabe T, Shimizu M et al.. Echocardiographic assessment of PDA shunt flow pattern in premature infants.  Arch Dis Child Fetal Neonatal Ed. 1997;  77 F36-F40
• 17 Shah S S, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.  Cochrane Database Syst Rev. 2006;  (1) CD004213
• 18 Furzan J A, Reisch J, Tyson J E et al.. Incidence and risk factor for symptomatic patent ductus arteriosus among inborn very-low-birth-weight infants.  Early Hum Dev. 1985;  12 39-48
• 19 Van Overmeire B, Follens I, Hartmann S et al.. Treatment of patent ductus arteriosus with ibuprofen.  Arch Dis Child Fetal Neonatal Ed. 1997;  76 F179-F184
• 20 Van Overmeire B, Van de Broek H, Van Laer P et al.. Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome.  J Pediatr. 2001;  138 205-211
• 21 Vanhaesebrouck S, Zonnenberg I, Vandervoort P et al.. Conservative treatment for patent ductus arteriosus in the preterm.  Arch Dis Child Fetal Neonatal Ed. 2007;  92 F244-F247
• 22 Fujii A M, Brown E, Mirochnick M et al.. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus.  J Perinatol. 2002;  22 535-540
• 23 Paquette L, Friedlich P, Ramanathan R et al.. Concurrent use of indomethacin and dexamethasone increases the risk of spontaneous intestinal perforation in very low birthweight neonates.  J Perinatol. 2006;  26 486-492
• 24 Cotton R B. The relationship of symptomatic patent ductus arteriosus to respiratory distress in premature newborn infants.  Clin Perinatol. 1987;  14 621-633
• 25 Cotton R B, Lindstrom D P, Stahlman M T. Early prediction of symptomatic patent ductus arteriosus from perinatal risk factors: a discriminant analysis model.  Acta Paediatr Scand. 1981;  70 723-727
• 26 Kabra N S, Schmidt B, Roberts R S et al.. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.  J Pediatr. 2007;  150 229-234
• 27 Oh W, Poindexter B B, Perritt R et al.. Association between fluid intake and weight loss during the first ten days of life and risk of bronchopulmonary dysplasia in extremely low birth weight infants.  J Pediatr. 2005;  147 786-790
• 28 Bell E F, Acarregui M J. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants.  Cochrane Database Syst Rev. 2008;  (1) CD000503
• 29 Bell E F, Warburton D, Stonestreet B S et al.. Effect on fluid administration on the development of symptomatic patent ductus arteriosus and congestive heart failure in premature infants.  N Engl J Med. 1980;  302 598-604
• 30 Gonzalez A, Sosenko I RS, Chandar J et al.. Influence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less.  J Pediatr. 1996;  128 470-478
• 31 Cordero L, Nankervis C A, DeLooze D et al.. Indomethacin prophylaxis or expectant treatment of patent ductus arteriosus in extremely low birth weight infants?.  J Perinatol. 2007;  27 158-163